|
Cabaletta Bio Inc (NASDAQ: CABA) |
|
Cabaletta Bio Inc
CABA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Cabaletta Bio Inc 's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 13.29 %
Cabaletta Bio Inc net loss increased from $-16 millions, to $-31 millions in III. Quarter 2024,
• More on CABA's Growth
|
|
Cabaletta Bio Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 2.22 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.69.
• More on CABA's Valuation
|
|
|
|
|
Cabaletta Bio Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 2.22 in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.69.
Cabaletta Bio Inc Price to Book Ratio is at 0.7 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.02
• More on CABA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com